Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612215 | Elacestrant in Advanced Triple Positive Breast Cancer | recruiting | Phase 1 / Phase 2 | 50 | NYU Langone HealthOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04523857 | ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer(ABBY) | recruiting | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05472792 | Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy(CAMERAN) | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06631092 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 28 | NEC Bio B.VINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT07605728 | Probiotics for Abemaciclib-Induced Abdominal Discomfort. | recruiting | Phase 2 | 80 | Leeuwenhoek Laboratories Co. Ltd.INDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | recruiting | Phase 1 / Phase 2 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer(DIAMOND) | recruiting | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06963905 | Saci Nivo Rela for TNBC(SIMONE) | recruiting | Phase 1 / Phase 2 | 60 | Yale UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07601178 | QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 34 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06860815 | Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | recruiting | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06502691 | [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06897488 | EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | recruiting | Phase 2 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06023576 | A Study of Blood Pressure Control During Cancer Treatment | recruiting | Phase 2 | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07053085 | A Study of Surgery and Radiotherapy in People With Breast Cancer | recruiting | Phase 2 | 178 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07395336 | Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)(COMBINE-01) | recruiting | Phase 2 | 26 | European Institute of OncologyOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | recruiting | Phase 2 | 46 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07581834 | Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study | recruiting | Phase 2 | 2,000 | Fujian Cancer HospitalOTHER_GOV | 1 | May 12, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07258108 | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04771871 | MicroRNA Profiles in Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 42 | University College Hospital, IbadanOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 484 | Canadian Cancer Trials GroupNETWORK | 1 | May 7, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03990896 | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06727773 | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06845319 | NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients(NeoCARD) | recruiting | Phase 2 | 43 | Medical University of South CarolinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer(NeoTHERa) | recruiting | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05716516 | STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)(ESTHER) | recruiting | Phase 2 | 36 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04305834 | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05608252 | VS-6766+Abema+Fulv in Met HR+/HER- BC | recruiting | Phase 1 / Phase 2 | 63 | Adrienne G. WaksOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07276880 | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer(P-RAD(+)TN-DCT) | recruiting | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05982093 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer(SOLTI-2104) | recruiting | Phase 2 | 96 | SOLTI Breast Cancer Research GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | recruiting | Phase 2 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07443943 | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial(AIMSS-RPS) | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05455619 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer(Amelia-1) | recruiting | Phase 1 / Phase 2 | 52 | SynDevRx, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease(PREDICT-RD) | recruiting | Phase 2 | 78 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07123649 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study(I-MAMMO) | recruiting | Phase 2 | 364 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07378306 | FMD and Neoadjuvant Chemo-immunotherapy in TNBC(FACT-TN) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05491226 | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | recruiting | Phase 2 | 35 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06134375 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | recruiting | Phase 1 / Phase 2 | 204 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06374459 | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | recruiting | Phase 1 / Phase 2 | 152 | Washington University School of MedicineOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540533 | A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer(2025-370) | recruiting | Phase 2 | 92 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06042569 | Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | recruiting | Phase 2 | 174 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2026source: clinicaltrials